IGIS Asia Investment Management has teamed up with South Korean bio-pharma group CHA Bio to form an Asia-Pacific life-science real estate investment partnership.

The new platform plans to develop and invest in life-science assets, including R&D and manufacturing facilities, hospitals, medical offices, and other healthcare centers in Asia-Pacific, including metropolitan cities in South Korea.

IGIS said it expects to set up the Korea Life Science Investment Platform (KLSIP) to support the venture with capital to develop facilities in South Korea.

To read the latest edition of the latest IPE Real Assets magazine click here.